Clinical Trial: 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Open Label Trial Of 3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS)

Brief Summary: The purpose of this study is to determine the effectiveness and adverse effects of 3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS).

Detailed Summary:
Sponsor: Lahey Clinic

Current Primary Outcome: Increase in strength and autonomic symptoms [ Time Frame: 1-10 years ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Lahey Clinic

Dates:
Date Received: March 30, 2009
Date Started: June 2001
Date Completion: June 2020
Last Updated: June 22, 2016
Last Verified: June 2016